The factors associated with treatment effect and indication for patients with ribavirin intolerance in simeprevir, pegylated interferon and ribavirin therapy for patients with chronic hepatitis C

2016 Fiscal Year Final Research Report

• Project/Area Number: 26860503
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: Osaka University
• Principal Investigator: OZE Tsugiko 大阪大学, 医学系研究科, 特任助教 (30623582)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: C型肝炎ウイルス / C型慢性肝炎治療 / 薬剤耐性変異 / シメプレビル・ペグインターフェロン・リバビリン

Outline of Final Research Achievements

This prospective, multicenter study was conducted by Osaka Liver Forum consisting of Osaka University Hospital and affiliated hospitals of Osaka University in order to examine the factors associated with treatment effect and treatment strategy of simeprevir, pegylated interferon and ribavirin for chronic hepatitis C. In naive, sustained virologic response rate was significantly higher with ribavirin dose-dependently in IL28B non-TT patients. In patients with non-response to pegylated interferon and ribavirin, extended treatment until 48 weeks improves sustained virologic response rate significantly in patients with positive HCV-RNA at treatment week 2. In patients with failed to telaprevir, pegylated interferon and ribavirin, ultra-deep sequencing analysis revealed that there were no cross-resistance between teralprevir and simeprevir, and telaprevir-resistant variants may have no influence on the effect of simeprevir-based therapy after failure of telaprevir-based therapy.

Free Research Field

医学　C型肝炎ウイルス　C型慢性肝炎治療